Advertisement

Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle

      Abstract

      Antisense oligodeoxynucleotide against the splicing enhancer sequence (SES) in exon 19 of the dystrophin gene have been shown to induce exon 19 skipping and promote the expression of internally deleted dystrophin by correcting the translational reading frame in the cultured Duchenne muscular dystrophy (DMD) myocytes with the deletion of exon 20. Transfection of the antisense oligodeoxynucleotide, therefore, has been proposed as a promising means for therapeutic modification of dystrophin mRNA of DMD, a fatal disorder caused by defects in the dystrophin gene. A systemic delivery method targeting the large number of diseased muscles remains to be established for clinical application of antisense oligodeoxynucleotide. In this study, we investigated capability of oligodeoxynucleotide transfer into the skeletal muscles of mdx mouse, a mouse model of DMD. Thirty-one mer phosphorothioate oligodeoxynucleotide complementary to the SES of dystrophin exon 19 was intraperitoneally administered to mdx mice without any carrier. Histochemical study disclosed that fluorescence-labeled oligodeoxynucleotide appeared in the nuclei of femoral skeletal muscle cell at the second day after injection of 20 mg/kg BW oligodeoxynucleotide, and still visible at 14th day. Reverse transcription (RT)-PCR analysis of dystrophin transcript in these cells disclosed that a proportion of it showed skipping of exon 19 from second to seventh day after injection. These results showed that the intraperitoneally administered oligodeoxynucleotide could be transfected to nucleus of mdx skeletal muscle without any carrier and was able to induce exon skipping in vivo.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Monaco A.P.
        • Bertelson C.J.
        • Liechti-Gallati S.
        • Moser H.
        • Kunkel L.M.
        An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.
        Genomics. 1988; 2: 90-95
        • Pramono Z.A.
        • Takeshima Y.
        • Alimsardjono H.
        • Ishii A.
        • Takeda S.
        • Matsuo M.
        Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence.
        Biochem Biophys Res Commun. 1996; 226: 445-449
        • Takeshima Y.
        • Wada H.
        • Yagi M.
        • Ishikawa Y.
        • Minami R.
        • Nakamura H.
        • et al.
        Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient.
        Brain Dev. 2001; 23: 788-790
        • van-Deutekom J.C.
        • Bremmer-Bout M.
        • Janson A.A.
        • Ginjaar I.B.
        • Baas F.
        • den-Dunnen J.T.
        • et al.
        Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
        Hum Mol Genet. 2001; 10: 1547-1554
        • Aartsma-Rus A.
        • Bremmer-Bout M.
        • Janson A.A.M.
        • den-Dunnen J.T.
        • van-Ommen G.J.B.
        • van-Deutekom J.C.T.
        Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
        Neuromuscul Disord. 2002; 12 (S71–7)
        • Sicinski P.
        • Geng Y.
        • Ryder-Cook A.S.
        • Barnard E.A.
        • Darlison M.G.
        • Barnard P.J.
        The molecular basis of muscular dystrophy in the mdx mouse: a point mutation.
        Science. 1989; 244: 1578-1580
        • Matsuda R.
        • Nishikawa A.
        • Tanaka H.
        Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle.
        J Biochem (Tokyo). 1995; 118: 959-964
        • Matsuo M.
        • Masumura T.
        • Nishio H.
        • Nakajima T.
        • Kitoh Y.
        • Takumi T.
        • et al.
        Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe.
        J Clin Invest. 1991; 87: 2127-2131
        • Takeshima Y.
        • Nishio H.
        • Sakamoto H.
        • Nakamura H.
        • Matsuo M.
        Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe.
        J Clin Invest. 1995; 95: 515-520
        • Surono A.
        • Takeshima Y.
        • Wibawa T.
        • Ikezawa M.
        • Nonaka I.
        • Matsuo M.
        Circular dystrophin RNAs consisting of exons that were skipped by alternative splicing.
        Hum Mol Genet. 1999; 8: 493-500
        • Askari F.K.
        • McDonnell W.M.
        Antisense-oligonucleotide therapy.
        N Engl J Med. 1996; 334: 316-318
        • Dominski Z.
        • Kole R.
        Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
        Proc Natl Acad Sci USA. 1993; 90: 8673-8677
        • Loke S.L.
        • Stein C.A.
        • Zhang X.H.
        • Mori K.
        • Nakanishi M.
        • Subasinghe C.
        • et al.
        Characterization of oligonucleotide transport into living cells.
        Proc Natl Acad Sci USA. 1989; 86: 3474-3478
        • Yakubov L.A.
        • Deeva E.A.
        • Zarytova V.F.
        • Ivanova E.M.
        • Ryte A.S.
        • Yurchenko L.V.
        • et al.
        Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?.
        Proc Natl Acad Sci USA. 1989; 86: 6454-6458
        • Raynaud F.I.
        • Orr R.M.
        • Goddard P.M.
        • Lacey H.A.
        • Lancashire H.
        • Judson I.R.
        • et al.
        Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
        J Pharmacol Exp Ther. 1997; 281: 420-427
        • Agrawal S.
        • Temsamani J.
        • Tang J.Y.
        Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
        Proc Natl Acad Sci USA. 1991; 88: 7595-7599
        • Qian M.
        • Chen S.H.
        • von Hofe E.
        • Gallo J.M.
        Pharmacokinetics and tissue distribution of a DNA-methyltransferase antisense (MT-AS) oligonucleotide and its catabolites in tumor-bearing nude mice.
        J Pharmacol Exp Ther. 1997; 282: 663-670
        • Phillips J.A.
        • Craig S.J.
        • Bayley D.
        • Christian R.A.
        • Geary R.
        • Nicklin P.L.
        Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.
        Biochem Pharmacol. 1997; 54: 657-668
        • Peng B.
        • Andrews J.
        • Nestorov I.
        • Brennan B.
        • Nicklin P.
        • Rowland M.
        Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat.
        Antisense Nucleic Acid Drug Dev. 2001; 11: 15-27
        • Geary R.S.
        • Yu R.Z.
        • Levin A.A.
        Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
        Curr Opin Investig Drugs. 2001; 2: 562-573
        • Reed J.C.
        • Stein C.
        • Subasinghe C.
        • Haldar S.
        • Croce C.M.
        • Yum S.
        • et al.
        Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides.
        Cancer Res. 1990; 50: 6565-6570
        • Qu X.
        • Kirken R.A.
        • Tian L.
        • Wang M.
        • Bennett C.F.
        • Stepkowski S.M.
        Selective inhibition of IL-2 gene expression by IL-2 antisense oligonucleotides blocks heart allograft rejection.
        Transplantation. 2001; 72: 915-923
        • Aartsma-Rus A.
        • Janson A.A.
        • Kaman W.E.
        • Bremmer-Bout M.
        • den Dunnen J.T.
        • Baas F.
        • et al.
        Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.
        Hum Mol Genet. 2003; 12: 907-914
        • Aartsma-Rus A.
        • Janson A.A.
        • Kaman W.E.
        • Bremmer-Bout M.
        • van Ommen G.J.
        • den Dunnen J.T.
        • et al.
        Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.
        Am J Hum Genet. 2004; 74: 83-92
        • Pirollo K.F.
        • Rait A.
        • Sleer L.S.
        • Chang E.H.
        Antisense therapeutics: from theory to clinical practice.
        Pharmacol Ther. 2003; 99: 55-77
        • Yagi M.
        • Takeshima Y.
        • Surono A.
        • Takagi M.
        • Koizumi M.
        • Matsuo M.
        Chimeric RNA and 2′-O, 4′-C-ethylene-bridged nucleic acids have stronger activity than phosphorothioate oligodeoxynucleotides in induction of exon 19 skipping in dystrophin mRNA.
        Oligonucleotides. 2004; 14: 33-40